AIM
VYNE icon

ARK Investment Management’s VYNE Therapeutics VYNE Stock Holding History

ARK Investment Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,018
Closed -$197K – 216
2020
Q1 		$197K Buy
+1,018
New +$319K ﹤0.01% 174

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ARK Investment Management's VYNE Position: Q2 2020 in Review

ARK Investment Management sold out of VYNE Therapeutics (VYNE) in Q2 2020, closing a stake of 1,018 shares — an estimated $197K sold.

ARK Investment Management first reported a position in VYNE in Q1 2020 and held it in 1 quarter. The position peaked at $197K in Q1 2020. 106 funds tracked by Wall St. Rank hold VYNE as of Q2 2020.

  • ARK Investment Management reported no remaining VYNE Therapeutics position as of Q2 2020 after selling out during the quarter.
  • ARK Investment Management sold 1,018 VYNE Therapeutics shares in Q2 2020, an estimated $197K.
  • ARK Investment Management first reported a position in VYNE Therapeutics in Q1 2020 and held it in 1 quarter.
  • ARK Investment Management's VYNE Therapeutics position peaked at $197K in Q1 2020.
  • 106 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2020.

Based on ARK Investment Management's 13F filing for Q2 2020, filed 11 Aug 2020.